Format

Send to

Choose Destination
Leuk Lymphoma. 2016 Oct;57(10):2359-69. doi: 10.3109/10428194.2015.1135431. Epub 2016 Jan 12.

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Author information

1
a University of Arizona Cancer Center , Tucson , AZ , USA ;
2
b SWOG Statistical Center , Seattle , WA , USA ;
3
c Department of Pathology , University of Arizona , Tucson , AZ , USA ;
4
d Wilmot Cancer Center , University of Rochester , Rochester , NY , USA ;
5
e Fox Chase Cancer Center - Temple Health , Philadelphia , PA , USA ;
6
f University of Arkansas for Medical Sciences , Little Rock , AK , USA ;
7
g Department of Medicine, University of Chicago , Chicago , IL , USA.

Abstract

Recent advances in diffuse large B-cell lymphomas (DLBCL) have underscored the importance of tumor microenvironment in escaping host anti-tumor responses. One mechanism is loss of major histocompatibility Class II antigens (MHCII) associated with decreased tumor infiltrating T lymphocytes (TIL) and poor survival. Transcription of MHCII is controlled by CIITA which in turn is regulated by histone acetylation. In this study, we hypothesized that HDAC inhibition with belinostat increases MHCII, CIITA expression, TIL and improves patient outcomes. Primary objective was evaluation of toxicity and response. Twenty-two patients were enrolled for the study. Belinostat was well tolerated with mild toxicity. Two partial responses were observed at 5, 13 months after registration for an overall response rate (ORR) (95% CI) of 10.5% (1.3-33.1%), and three patients had stable disease for 4.7, 42.3+, and 68.4 + months with minimum 3-year follow-up. Included correlative studies support the hypothesis and serve as the basis for SWOG S0806 combining vorinostat with R-CHOP.

KEYWORDS:

CIITA; DLBCL; HDAC inhibition; MHC Class II expression; SWOG; non-Hodgkin lymphoma

PMID:
26758422
PMCID:
PMC5140034
DOI:
10.3109/10428194.2015.1135431
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center